India Medtronic, a wholly owned subsidiary of Minneapolis-based Medtronic plc, announced the launch of the TruClear system, a mechanical hysteroscopic tissue removal system used for the safe and effective treatment of intra uterine abnormalities.
Some of these abnormalities commonly seen include fibroids, polyps, retained products of conception, adhesions, malignancies, or hyperplasia.
One of the symptoms of intra uterine abnormalities is abnormal uterine bleeding (AUB) which is reported to occur in 9-14% women between menarche and menopause. The prevalence varies in each country. In India, the reported prevalence of AUB is around 17.9%.
Unlike other intrauterine abnormality treatment options that use a high-frequency electric current, the TruClear system uses a simple mechanical approach to remove intrauterine tissue. Hence, there is no scarring of the uterine lining from thermal energy or electrical energy, providing better hope of preserving the uterus for the future.
Abhishek Bhargava, director, Surgical, Patient Monitoring, Respiratory Interventions & ENT, Medtronic India said, “TruClear system is a new addition to our GYN and women’s health portfolio in India. The system is built to facilitate a less invasive and effective way of treating intra uterine pathologies, giving patients the choice to retain the organ and go back to routine faster. Its precision and enhanced visibility provides gynecologists much needed comfort and helps avoid complications, yielding better patient outcomes.”
Last updated: December 26th, 2025
